by Peter Ciszewski | Dec 20, 2017
The Food and Drug Administration granted regular approval to Exelixis’ Cabometyx (cabozantinib) for treatment of patients with advanced renal cell carcinoma (RCC). The FDA previously approved Cabometyx in 2016 for treatment of patients with advanced RCC who have...
by Peter Ciszewski | Dec 20, 2017
The Food and Drug Administration granted accelerated approval to bosutinib (Pfizer) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). Approval was based on data from an...
by Peter Ciszewski | Dec 19, 2017
Ovid Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OV101 for the treatment of Angelman syndrome. “This designation is an important milestone for both Ovid and the Angelman community as it enables...
by Peter Ciszewski | Dec 19, 2017
Amit Rakhit, MD, Chief Medical and Portfolio Officer at Ovid Therapeutics, discusses how his company values working with patient groups. Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families...
by Peter Ciszewski | Dec 19, 2017
Saqib Islam, Chief Financial and Business Officer at SpringWorks Therapeutics discusses the formation of this new biotech company. SpringWorks Therapeutics is dedicated to developing innovative potential new treatments for underserved patient communities. The...
